Barclays analyst Gena Wang lowered the firm’s price target on Moderna (MRNA) to $25 from $31 and keeps an Equal Weight rating on the shares following the Q3 report.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA:
- Moderna Reports Q3 2025 Financial Results
- Moderna’s Earnings Call: Balancing Achievements and Challenges
- Moderna’s Strategic Challenges and Opportunities: A Hold Rating Amid Mixed Product Results and Market Uncertainties
- SPY ETF Daily Update, 11/6/2025
- Midday Fly By: Qualcomm reports Q4 beat, Schwab acquires Forge